Phospholipase domain containing 3, or PNPLA3,
polymorphism was a predictor for steatosis among Spanish patients with
hepatitis C virus genotype 1, according to study data.
Researchers from various medical centers in
Spain sought to determine the relationship between PNPLA3 and steatosis
and fibrosis after therapy with pegylated interferon plus ribavirin
among a cohort of patients with HCV.
is frequent among patients with chronic hepatitis C virus; its
prevalence is higher than general population and individuals with other
chronic liver diseases,” the researchers wrote
Labels: GT1, PNPLA3, polymorphisms, steatosis